Patient P-01652
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
81%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S12
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient declined — Not now
- Day 59 ME-01 recommended — Monitoring Escalation ME-01
- Day 60 Patient accepted — Started ME-01 in the companion
- Day 63 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- GI instability-13
- Nutritional resilience+7
- Inflammatory activity-6
- Toxicity+3
What helped?
- GI Support Protocol GI-04Day 57Declined by patient
- Monitoring Escalation ME-01Day 59Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
84%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 61 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 28/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 56
- WearableHRV 25 ms, trending down
- Autonomic recovery ↑45
- WearableResting HR 77 bpm
- Wearable980 steps/day
- Drug metabolism and exposure ↑20
- BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 28/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 18 ms
- Sleep
- 6.4 h
- Steps
- 852
- Resting HR
- 81 bpm
Daily log: GI score 61, nutritional resilience 44, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01440 | 48% | S12 | GI-04 | no change | 51 |
| P-01810 | 48% | S05 | NP-02 | improved | 43 |
| P-01462 | 47% | S14 | NP-02 | improved | 47 |
| P-01564 | 46% | S14 | ME-01 | improved | 39 |
| P-01576 | 46% | S14 | NP-02 | no change | 49 |
| P-01728 | 45% | S14 | SC-12 | improved | 41 |
| P-01834 | 45% | S14 | NP-02 | improved | 44 |
| P-01364 | 44% | S14 | GI-04 | improved | 49 |
| P-01402 | 44% | S04 | GI-04 | improved | 37 |
| P-01656 | 44% | S14 | ME-01 | improved | 41 |
| P-01813 | 44% | S01 | NP-02 | no change | 40 |
| P-01872 | 44% | S14 | NP-02 | improved | 47 |